TSE:VRX - Valeant Pharmaceuticals International Stock Price, Price Target & More

C$21.94 0.00 (0.00 %)
(As of 04/20/2018 04:00 PM ET)
Previous CloseC$21.94
Today's RangeC$21.62 - C$22.13
52-Week RangeC$11.20 - C$30.56
Volume615,300 shs
Average Volume1.53 million shs
Market CapitalizationC$7.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.76

About Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolTSE:VRX
CUSIPN/A
Phone+1-514-7446792

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins58.58%
Return on Equity112.73%
Return on Assets12.76%

Miscellaneous

EmployeesN/A
Outstanding Shares348,840,000

How to Become a New Pot Stock Millionaire

Valeant Pharmaceuticals International (TSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals International's stock symbol?

Valeant Pharmaceuticals International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals International's earnings last quarter?

Valeant Pharmaceuticals International Inc (TSE:VRX) issued its quarterly earnings results on Wednesday, February, 28th. The specialty pharmaceutical company reported $1.24 EPS for the quarter, meeting analysts' consensus estimates of $1.24. The specialty pharmaceutical company had revenue of $2.75 billion for the quarter, compared to analyst estimates of $2.73 billion. Valeant Pharmaceuticals International had a return on equity of 112.73% and a net margin of 58.58%. View Valeant Pharmaceuticals International's Earnings History.

When is Valeant Pharmaceuticals International's next earnings date?

Valeant Pharmaceuticals International is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Valeant Pharmaceuticals International.

What price target have analysts set for VRX?

4 brokerages have issued 1 year price objectives for Valeant Pharmaceuticals International's stock. Their forecasts range from C$19.00 to C$25.50. On average, they expect Valeant Pharmaceuticals International's share price to reach C$22.50 in the next year. View Analyst Ratings for Valeant Pharmaceuticals International.

Who are some of Valeant Pharmaceuticals International's key competitors?

Who are Valeant Pharmaceuticals International's key executives?

Valeant Pharmaceuticals International's management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. J. Michael Pearson, Former Chief Exec. Officer (Age 59)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 46)

Has Valeant Pharmaceuticals International been receiving favorable news coverage?

Headlines about VRX stock have trended somewhat positive on Saturday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Valeant Pharmaceuticals International earned a media sentiment score of 0.02 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 46.28 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Valeant Pharmaceuticals International?

Shares of VRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Valeant Pharmaceuticals International's stock price today?

One share of VRX stock can currently be purchased for approximately C$21.94.

How big of a company is Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International has a market capitalization of C$7.69 billion.

How can I contact Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.


MarketBeat Community Rating for Valeant Pharmaceuticals International (VRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  473
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals International and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Valeant Pharmaceuticals International (TSE:VRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Valeant Pharmaceuticals International in the last 12 months. Their average twelve-month price target is C$22.50, suggesting that the stock has a possible upside of 2.55%. The high price target for VRX is C$25.50 and the low price target for VRX is C$19.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.502.502.502.20
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$22.50C$22.50C$22.50C$22.50
Price Target Upside: 2.55% upside18.86% upside18.86% upside44.69% upside

Valeant Pharmaceuticals International (TSE:VRX) Consensus Price Target History

Price Target History for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE:VRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/8/2017Royal Bank of CanadaReiterated RatingSector PerformC$23.00View Rating Details
11/8/2017TD SecuritiesUpgradeHold -> BuyC$25.50View Rating Details
6/29/2017Cantor FitzgeraldReiterated RatingOverweightView Rating Details
5/10/2017ScotiabankBoost Price TargetSector PerformC$19.00View Rating Details
12/15/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Valeant Pharmaceuticals International (TSE:VRX) Earnings History and Estimates Chart

Earnings by Quarter for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE VRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018C$0.85N/AView Earnings Details
2/28/2018Q4 2017C$1.24C$1.24C$2.73 billionC$2.75 billionViewN/AView Earnings Details
11/7/2017Q3 2017C$1.13C$1.30C$2.74 billionC$2.78 billionViewN/AView Earnings Details
8/8/2017Q2 2017C$1.28C$1.41C$2.94 billionC$3.00 billionViewN/AView Earnings Details
5/9/2017Q1 2017C$3.71C$2.79 billionViewN/AView Earnings Details
2/28/2017Q4 2016C$1.68C$3.21 billionViewN/AView Earnings Details
11/8/2016Q3 2016C$2.02C$3.23 billionViewN/AView Earnings Details
8/9/2016Q2 2016C$1.81C$3.82 billionC$3.12 billionViewN/AView Earnings Details
6/7/2016Q1 2016C$2.04C$1.74C$3.14 billionC$3.26 billionViewN/AView Earnings Details
3/15/2016Q4 2015C$3.24C$3.60 billionViewN/AView Earnings Details
10/19/2015Q3 2015C$3.50C$3.62C$3.62 billionC$3.74 billionViewN/AView Earnings Details
7/23/2015Q2 2015C$3.09C$3.17C$3.36 billionViewN/AView Earnings Details
4/29/2015Q1 2015C$2.82C$2.64 billionViewN/AView Earnings Details
2/22/2015Q4 2014C$3.30C$2.86 billionViewN/AView Earnings Details
10/20/2014Q3 2014C$2.20C$2.32 billionViewN/AView Earnings Details
7/31/2014Q2 2014C$1.98C$2.10 billionViewN/AView Earnings Details
5/8/2014C$1.83C$1.90C$2.05 billionViewN/AView Earnings Details
2/27/2014Q4 2013C$2.18C$2.39C$2.29 billionViewN/AView Earnings Details
10/31/2013Q3 2013C$1.47C$1.47C$1.71 billionC$1.61 billionViewN/AView Earnings Details
8/7/20132Q13C$0.03C$1.15 billionC$1.14 billionViewN/AView Earnings Details
5/2/2013Q1 2013C$1.28C$1.31C$1.10 billionC$1.08 billionViewN/AView Earnings Details
2/28/2013Q4 2012C$1.24C$1.23ViewN/AView Earnings Details
11/2/2012Q3 2012C$1.11C$1.11ViewN/AView Earnings Details
8/2/2012Q2 2012C$1.00C$1.02ViewN/AView Earnings Details
5/3/2012Q1 2012C$0.88C$1.12ViewN/AView Earnings Details
2/27/2012Q4 2011C$0.85C$0.90ViewN/AView Earnings Details
11/3/2011Q3 2011C$0.56C$0.63ViewN/AView Earnings Details
8/4/2011Q2 2011C$0.66ViewN/AView Earnings Details
5/9/2011Q1 2011C$0.51C$0.47ViewN/AView Earnings Details
2/24/2011Q4 2010C$0.49ViewN/AView Earnings Details
11/4/2010Q3 2010C$0.31C($0.28)ViewN/AView Earnings Details
8/5/2010Q2 2010C$0.35ViewN/AView Earnings Details
5/6/2010Q1 2010C$0.27C$0.55ViewN/AView Earnings Details
8/6/2009Q2 2009C$0.40C$0.37ViewN/AView Earnings Details
5/8/2009Q1 2009C$2.18C$0.32ViewN/AView Earnings Details
2/26/2009Q4 2008C$0.39C$0.42ViewN/AView Earnings Details
11/6/2008Q3 2008C$0.26C$0.37ViewN/AView Earnings Details
5/8/2008Q1 2008C$0.38C$0.43ViewN/AView Earnings Details
3/13/2008Q4 2007C$0.40C$0.44ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Valeant Pharmaceuticals International (TSE:VRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Valeant Pharmaceuticals International (TSE VRX) Insider Trading and Institutional Ownership History

Insider Trading History for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE VRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Joseph PapaDirectorBuy30,000C$16.05C$481,500.00
3/13/2018Paul HerendeenInsiderBuy15,000C$16.10C$241,500.00
11/17/2017Schutter Richard Urbain DeDirectorBuy10,000C$14.33C$143,300.00
8/21/2017Schutter Richard Urbain DeDirectorBuy4,900C$14.35C$70,315.00
8/9/2017John PaulsonDirectorSell24,700C$14.66C$362,102.00
5/11/2017Schutter Richard Urbain DeDirectorBuy20,000C$13.90C$278,000.00
3/15/2017Schutter Richard Urbain DeDirectorBuy10,000C$10.80C$108,000.00
11/5/2015J. Michael PearsonDirectorSell350,000C$0.00C$0.00
10/21/2015Ron FarmerDirectorBuy1,000C$193.00C$193,000.00
5/26/2015Whitaker AnneInsiderBuy2,500C$234.00C$585,000.00
5/4/2015Robert Roswell Chai-OnnInsiderSell90,938C$222.54C$20,237,433.46
(Data available from 1/1/2013 forward)

Headlines

Valeant Pharmaceuticals International (TSE VRX) News Headlines

Source:
DateHeadline
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE ProgramBausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program
finance.yahoo.com - April 19 at 8:19 AM
Why Valeant Pharmaceuticals Intl Inc. Stock’s 1-Year Return of 71% Could Be Just the BeginningWhy Valeant Pharmaceuticals Intl Inc. Stock’s 1-Year Return of 71% Could Be Just the Beginning
www.fool.ca - April 16 at 5:21 PM
Valeant Pharma (VRX) to Redeem $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020Valeant Pharma (VRX) to Redeem $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
www.streetinsider.com - April 14 at 5:08 PM
Paulson, Ackman and Sequoia: The Investors Who Took a Beating on ValeantPaulson, Ackman and Sequoia: The Investors Who Took a Beating on Valeant
finance.yahoo.com - April 13 at 5:29 PM
Valeant Pharmaceuticals International Inc’s (NYSE:VRX) Insiders Ramped Up Holdings – Should You?Valeant Pharmaceuticals International Inc’s (NYSE:VRX) Insiders Ramped Up Holdings – Should You?
finance.yahoo.com - April 13 at 5:29 PM
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS ArbitrationArbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
finance.yahoo.com - April 12 at 5:36 PM
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
finance.yahoo.com - April 12 at 5:36 PM
Today’s Research Reports on Valeant Pharmaceuticals, CRH Medical, Covalon Technologies and DiaMedica TherapeuticsToday’s Research Reports on Valeant Pharmaceuticals, CRH Medical, Covalon Technologies and DiaMedica Therapeutics
finance.yahoo.com - April 10 at 8:31 AM
Valeant Pharmaceuticals: Getting Better?Valeant Pharmaceuticals: Getting Better?
finance.yahoo.com - April 6 at 5:39 PM
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior UveitisEyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis
finance.yahoo.com - April 6 at 5:39 PM
Is Valeant Pharmaceuticals Intl Inc. Still on Track?Is Valeant Pharmaceuticals Intl Inc. Still on Track?
www.fool.ca - March 31 at 5:29 PM
Can Valeant Pharmaceuticals Intl Inc. Sell its Way to Success?Can Valeant Pharmaceuticals Intl Inc. Sell its Way to Success?
www.fool.ca - March 24 at 5:12 PM
Valeant CEO compensation drops, was 138 times typical workers pay in 2017Valeant CEO compensation drops, was 138 times typical worker's pay in 2017
finance.yahoo.com - March 21 at 5:35 PM
Are Options Traders Betting on a Big Move in Valeant (VRX) Stock?Are Options Traders Betting on a Big Move in Valeant (VRX) Stock?
finance.yahoo.com - March 20 at 5:14 PM
Has Valeant Pharmaceuticals Intl Inc. Proven it Belongs in Your TFSA?Has Valeant Pharmaceuticals Intl Inc. Proven it Belongs in Your TFSA?
www.fool.ca - March 16 at 6:27 PM
Insider Buying: Valeant Pharmaceuticals Intl Inc (VRX) Insider Purchases 15,000 Shares of StockInsider Buying: Valeant Pharmaceuticals Intl Inc (VRX) Insider Purchases 15,000 Shares of Stock
www.americanbankingnews.com - March 14 at 10:41 PM
Joseph Papa Purchases 30,000 Shares of Valeant Pharmaceuticals Intl Inc (VRX) StockJoseph Papa Purchases 30,000 Shares of Valeant Pharmaceuticals Intl Inc (VRX) Stock
www.americanbankingnews.com - March 14 at 10:41 PM
Valeant Pharmaceuticals (VRX) Presents At Barclays Global Healthcare Conference 2018 - SlideshowValeant Pharmaceuticals (VRX) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 14 at 7:03 PM
CANADA STOCKS-TSX little changed as banks, Valeant give supportCANADA STOCKS-TSX little changed as banks, Valeant give support
finance.yahoo.com - March 14 at 7:03 PM
CANADA STOCKS-Toronto stocks flat as banks and Valeant lend supportCANADA STOCKS-Toronto stocks flat as banks and Valeant lend support
finance.yahoo.com - March 14 at 7:03 PM
How Valeant Pharmaceuticals Intl Inc Can Give You a 750% Return - Investorplace.comHow Valeant Pharmaceuticals Intl Inc Can Give You a 750% Return - Investorplace.com
www.investorplace.com - March 14 at 8:38 AM
New Incentive Program at Valeant Pharmaceuticals Intl Inc. Signals a New Culture That Investors Can Stand byNew Incentive Program at Valeant Pharmaceuticals Intl Inc. Signals a New Culture That Investors Can Stand by
www.fool.ca - March 13 at 7:14 PM
CANADA STOCKS-TSX ends higher with gold sharesCANADA STOCKS-TSX ends higher with gold shares
finance.yahoo.com - March 13 at 7:14 PM
Valeant Pharma (VRX) Launch Of Private Offering Of Senior NotesValeant Pharma (VRX) Launch Of Private Offering Of Senior Notes
www.streetinsider.com - March 12 at 6:35 PM
Netflix can be shorted back to $300, says well-known investor Andrew LeftNetflix 'can be shorted back to $300,' says well-known investor Andrew Left
finance.yahoo.com - March 12 at 6:35 PM
Valeant: When Good News Goes Bad?Valeant: When Good News Goes Bad?
finance.yahoo.com - March 12 at 6:35 PM
Valeant Nixes CEOs $29.8 Million Stock Award in Pay OverhaulValeant Nixes CEO's $29.8 Million Stock Award in Pay Overhaul
finance.yahoo.com - March 12 at 6:35 PM
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1250000000 Outstanding Principal ... - PR Newswire (press release)Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1250000000 Outstanding Principal ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 9:27 AM
Safkhet Capitals Quadir Is Still Short ValeantSafkhet Capital's Quadir Is Still Short Valeant
finance.yahoo.com - March 8 at 6:37 PM
Why Progenics Pharmaceuticals Jumped 15.2% on ThursdayWhy Progenics Pharmaceuticals Jumped 15.2% on Thursday
finance.yahoo.com - March 8 at 6:37 PM
Sanpower Chairman Not Concerned By China, U.S. Trade WarSanpower Chairman 'Not Concerned' By China, U.S. Trade War
finance.yahoo.com - March 7 at 6:32 PM
Valeant Pharmaceuticals Intl Inc (VRX) Expected to Earn FY2018 Earnings of $3.83 Per ShareValeant Pharmaceuticals Intl Inc (VRX) Expected to Earn FY2018 Earnings of $3.83 Per Share
www.americanbankingnews.com - March 7 at 11:50 AM
Does Deutsche Bank Finally Have It Right on Valeant?Does Deutsche Bank Finally Have It Right on Valeant?
www.msn.com - March 5 at 5:48 PM
How Valeant Finally Won Over A Longtime BearHow Valeant Finally Won Over A Longtime Bear
finance.yahoo.com - March 5 at 5:48 PM
Deutsche Bank: buy ValeantDeutsche Bank: buy Valeant
finance.yahoo.com - March 5 at 5:48 PM
Valeant Pharmaceuticals Lost A Battle, Not The War - Seeking AlphaValeant Pharmaceuticals Lost A Battle, Not The War - Seeking Alpha
seekingalpha.com - March 4 at 6:24 PM
Could Valeants Stock Blow Up by 40%?Could Valeant's Stock Blow Up by 40%?
finance.yahoo.com - March 1 at 5:49 PM
Why Valeant Pharma Might Be Wearing Rose-Colored GlassesWhy Valeant Pharma Might Be Wearing Rose-Colored Glasses
finance.yahoo.com - March 1 at 5:49 PM
Valeant Pharmaceuticals Intl Inc. Q4 Earnings Review: Hold on TightValeant Pharmaceuticals Intl Inc. Q4 Earnings Review: Hold on Tight
www.fool.ca - February 28 at 6:01 PM
Valeant Pharmaceuticals International, Inc. 2017 Q4 - Results - Earnings Call SlidesValeant Pharmaceuticals International, Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 28 at 6:01 PM
Here's What Caused Valeant Pharmaceuticals' 11.4% Drop TodayHere's What Caused Valeant Pharmaceuticals' 11.4% Drop Today
finance.yahoo.com - February 28 at 6:01 PM
CANADA STOCKS-TSX tumbles as energy, Valeant shares weighCANADA STOCKS-TSX tumbles as energy, Valeant shares weigh
finance.yahoo.com - February 28 at 6:01 PM
Valeant misses Street 4Q forecastsValeant misses Street 4Q forecasts
finance.yahoo.com - February 28 at 8:21 AM
Valeant Earnings: Tomorrow Will Show Just How Far Its Come…Or NotValeant Earnings: Tomorrow Will Show Just How Far It's Come…Or Not
finance.yahoo.com - February 27 at 5:52 PM
Valeant Pharmaceuticals Intl Inc. Sure Has Fight in itValeant Pharmaceuticals Intl Inc. Sure Has Fight in it
www.fool.ca - February 26 at 5:42 PM
Will Valeant Pharmaceuticals' Turnaround Fizzle with Its Q4 Results?Will Valeant Pharmaceuticals' Turnaround Fizzle with Its Q4 Results?
finance.yahoo.com - February 25 at 6:17 PM
Is Valeant Pharmaceuticals International, Inc. a Buy?Is Valeant Pharmaceuticals International, Inc. a Buy?
finance.yahoo.com - February 23 at 5:55 PM
Why Valeant is growing its Raleigh teamWhy Valeant is growing its Raleigh team
finance.yahoo.com - February 21 at 5:25 PM
Valeant Pharmaceuticals Intl (VRX) to Release Earnings on WednesdayValeant Pharmaceuticals Intl (VRX) to Release Earnings on Wednesday
www.americanbankingnews.com - February 21 at 4:12 AM
VRX Crosses Above Average Analyst TargetVRX Crosses Above Average Analyst Target
www.nasdaq.com - February 16 at 5:16 PM

SEC Filings

Valeant Pharmaceuticals International (TSE:VRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Valeant Pharmaceuticals International (TSE VRX) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.